SavedAdd your journal

Journals / Mersin Üniversitesi Sağlık Bilimleri Dergisi / 2017 / Cilt: 10 Sayı: 3

Resveratrol ve kemik üzerine etkileri

Ayşe Özcan Küçük(MERSİN ÜNİVERSİTESİ)
Pages
228–237
Publication Date
2017-12-24
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Bu derlemenin amacı RSVL’nin kemik üzerine olan etkilerini değerlendirmektir.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Resveratrol (RSVL) çeşitli bitkilerden elde edilen doğal bir polifenolik bileşiktir.
📊
Key Findings & Data:RSVL’nin, anti-oksidan, anti-inflamatuar, anti-kanserojen, anti-viral, anti-diyabetik, anti-aging, kardiyoprotektif, nöroprotektif ve östrojenik etki gibi çeşitli yararlı etkileri bildirilmiştir.
💡
Conclusion & Impact:Bu derlemenin amacı RSVL’nin kemik üzerine olan etkilerini değerlendirmektir.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Resveratrol · kemik metabolizması · kemik kaybı

Özet

Resveratrol (RSVL) çeşitli bitkilerden elde edilen doğal bir polifenolik bileşiktir. RSVL’nin, anti-oksidan, anti-inflamatuar, anti-kanserojen, anti-viral, anti-diyabetik, anti-aging, kardiyoprotektif, nöroprotektif ve östrojenik etki gibi çeşitli yararlı etkileri bildirilmiştir. RSVL’nin klinik kullanımı ile ortaya çıkan çeşitli yararlı etkilerine ilaveten bu bileşiğin kemik metabolizması üzerine etkileri de bildirilmiştir. Bu derlemenin amacı RSVL’nin kemik üzerine olan etkilerini değerlendirmektir.

🔖

Cite This Article

Küçük, A. Ö. (2017). Resveratrol ve kemik üzerine etkileri. Mersin Üniversitesi Sağlık Bilimleri Dergisi, Cilt: 10 Sayı: 3, 228–237. https://doi.org/10.26559/mersinsbd.307036

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (54)

  1. Ribeiro FV, Ce´sar-Neto JB, Nociti Jr FH, Sallum EA, Sallum AW, De Toledo S, Casati MZ. Selective cyclooxygenase-2 inhibitor may impair bone healing around titanium implants in rats. J Periodontol 2006;77(10):1731–1735.
  2. Zupnik J, Kim SW, Ravens D, Karimbux N, Guze K. Factors associated with dental implant survival: a 4-year retrospective analysis. J Periodontol 2011;82(10):1390–1395. Claes L, Recknagel S, Ignatius A. Fracture healing under healthy and inflammatory conditions. Nat Rev Rheumatol 2012;8:133–43.
  3. Claes L, Recknagel S, Ignatius A. Fracture healing under healthy and inflammatory conditions. Nat Rev Rheumatol 2012;8:133–43.
  4. Kuroshima S, Kovacic BL, Kozloff KM, McCauley LK, Yamashita J. Intra-oral PTH administration promotes tooth extraction socket healing. J Dent Res 2013;92(6):553-559.
  5. O’Ryan FS, Lo JC. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. J Oral Maxillofac Surg 2012;70(8):1844-1853.
  6. Casarin RC, Casati MZ, Pimentel SP, Cirano FR, Algayer M, Pires PR, Ghiraldini B, Duarte PM, Ribeiro FV. Resveratrol improves bone repair by modulation of bone morphogenetic proteins and osteopontin gene expression in rats. Int J Oral Maxillofac Surg 2014;43(7):900-906.
  7. Al-Obaidi MM, Al-Bayaty FH, Al Batran R, Hassandarvish P, Rouhollahi E. Protective effect of ellagic acid on healing alveolar bone after tooth extraction in rat. A histological and immunohistochemical study. Arch Oral Biol 2014, 59: 987-99.
  8. Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release 2012;158(2):182-193.
  9. Nonomura S, Kanagawa H, Makimoto A. Chemical constituents of polygonaceous plants. I. Studies on the components of Ko-jokon (Polygonum cuspidatum SIEB. et ZUCC.). Yakugaku Zasshi 1963;83:988–990.
  10. Siemann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. Am J Enol Viticult 1992;43:49–52.
  11. Liu BL, Zhang X, Zhang W, Zhen HN. New enlightenment of French Paradox: resveratrol’s potential for cancer chemoprevention and anti-cancer therapy. Cancer Biol Ther 2007;6(12):1833–1836.
  12. La M, Wald N. Why heart disease mortality is low in France: The time lag explanation. Br Med J 1999;318(7196):1471-1476.
  13. Singh KC, Kumar A, LaVoie AL, Di Pipette DJ, Singh US. Diabetic complications in pregnancy: is resveratrol a solution? Exp Biol Med 2013;238(5):482-490.
  14. Yang T, Li S, Zhang X, Pang X, Lin Q, Cao J. Resveratrol, sirtuins, and viruses. Rev Med Virol 2015;25(6):431–445.
  15. Han G, Xia J, Gao J, Inagaki Y, Tang W, Kokudo N. Anti-tumor effects and cellular mechanisms of resveratrol. Drug Discov Ther 2015;9(1):1-12.
  16. Poulsen MM, Ornstrup MJ, Harsløf T, Jessen N, Langdahl BL, Richelsen B, Jørgensen JO, Pedersen SB. Short-term resveratrol supplementation stimulates serum levels of bone-specific alkaline phosphatase in obese non-diabetic men. Journal of Functional Foods 2014;6:305-310.
  17. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, Sharma K, Pleshko N, Woollett LA, Csiszar A, Ikeno Y, Couteur DL, Elliott PJ, Becker KG, Navas P, Ingram DK, Wolf NS, Ungvari Z, Sinclair DA, de Cabo R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008;8(2):157–168.
  18. Mobasheri A, Shakibaei M. Osteogenic effects of resveratrol in vitro: potential for the prevention and treatment of osteoporosis. Ann NY Acad Sci 2013;1290:59–66.
  19. Tseng PC, Hou SM, Chen RJ, Peng HW, Hsieh CF, Kuo ML, Yen ML. Resveratrol promotes osteogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis. J Bone Miner Res 2001;26(10):2552–2563.
  20. Shakibaei M, Shayan P, Busch F, Aldinger C, Buhrmann C, Lueders C, Mobasheri A. Resveratrol mediated modulation of Sirt-1/Runx2 promotes osteogenic differentiation of mesenchymal stem cells: potential role of Runx2 deacetylation. PLoS One. 2012;7(4):e35712.
  21. Kim HJ, Braun HJ, Dragoo JL. The effect of resveratrol on normal and osteoarthritic chondrocyte metabolism. Bone Joint Res 2014;3(3):51–59.
  22. Mizutani K, Ikeda K, Kawai Y, Yamori Y. Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun 1998; 253(3):859-863.
  23. Song LH, Pan W, Yu YH, Quarles LD, Zhou HH, Xiao ZS. Resveratrol prevents CsA inhibition of proliferation and osteoblastic differentiation of Mouse bone marrow-derived mesenchymal stem cells through an ER/NO/cGMP pathway. Toxicol In Vitro 2006;20(6):915–922.
  24. He X, Andersson G, Lindgren U, Li Y. Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW 264.7 cells through inhibition of ROS production. Biochem Biophys Res Commun 2010;401(3):356–1362.
  25. Durbin SM, Jackson JR, Ryan MJ, Gigliotti JC, Alway SE, Tou JC. Resveratrol supplementation influences bone properties in the tibia of hindlimb-suspended mature Fisher 344 × Brown Norway male rats. Appl Physiol Nutr Metab 2012;37(6): 1179-1188.
  26. Liu ZP, Li WX, Yu B, Huang J, Sun J, Huo JS, Liu CX. Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomised rat model. J Med Food 2005;8(1):14–19.
  27. Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T, Delaissé JM. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res 2005;65(21):9943–9952.
  28. Singh SU, Casper RF, Fritz PC, Sukhu B, Ganss B, Girard B Jr, Savouret JF, Tenenbaum HC. Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol. J Endocrinol 2000;167(1):183-193.
  29. Backesjo CM, Li Y, Lindgren U, Haldosen LA. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res 2006;21(7):993–1002.
  30. Dai Z, Li Y, Quarles LD, Song T, Pan W, Zhou H, Xiao Z. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine 2007;14(12):806-814.
  31. Lee YS, Kim YS, Lee SY, Kim GH, Kim BJ, Lee SH, Lee KU, Kim GS, Kim SW, Koh JM. AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts, Bone 2010;47(5):926–937.
  32. Zhou H, Shang L, Li X, Zhang X, Gao G, Guo C, Chen B, Liu Q, Gong Y, Shao C. Resveratrol augments the canonical Wnt signaling pathway in promoting osteoblastic differentiation of multipotent mesenchymal cells, Exp Cell Res 2009;315(17):2953–2962.
  33. Ornstrup MJ, Harsløf T, Sørensen L, Stenkjær L, Langdahl BL, Pedersen SB.Resveratrol Increases Osteoblast Differentiation In Vitro Independently of Inflammation.Calcif Tissue Int. 2016;99(2):155-163.
  34. Momken I, Stevens L, Bergouignan A, Desplanches D, Rudwill F, Chery I, Zahariev A, Zahn S, Stein TP, Sebedio JL, Pujos-Guillot E, Falempin M, Simon C, Coxam V, Andrianjafiniony T, Gauquelin-Koch G, Picquet F, Blanc S. Resveratrol prevents the wasting disorders of mechanical unloading by acting as a physical exercise mimetic in the rat. FASEB J 2011;25(10):3646–3660.
  35. Lin Q, Huang YM, Xiao BX, Ren GF. Effects of resveratrol on bone mineral density in ovarectomized rats. Int J Biomed Sci 2005;1(1):76-81.
  36. Mizutani K, Ikeda K, Kawai Y, Yamori Y. Protective effect of resveratrol on oxidative damage in male and female stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2001;28(1-2):55–59.
  37. Sehmisch S, Hammer F, Christoffel J, Seidlova-Wuttke D, Tezval M, Wuttke W, Stuermer KM, Stuermer EK. Comparison of the phytohormones genistein, resveratrol and 8-prenylnaringenin as agents for preventing osteoporosis. Planta Med 2008;74(8):794–801.
  38. Zhao H, Li X, Li N, Liu T, Liu J, Li Z, Xiao H, Li J. Long-term resveratrol treatment prevents ovariectomy induced osteopenia in rat without hyperplastic effects on the uterus. Br J Nutr 2014;111(5):836–846.
  39. Mizutani K, Ikeda K, Kawai Y, Yamori Y. Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo) 2000;46(2):78-83.
  40. Uysal T, Gorgulu S, Yagci A, Karslioglu Y, Gunhan O, Sagdic D. Effect of resveratrol on bone formation in the expanded inter-pre- maxillary suture: early bone changes. Orthod Craniofac Res 2011;14(2):80–87.
  41. Kolkesen Şahin Ö, Çina Aksoy M, Avunduk MC. Effects of resveratrol and cigarette smoking onbone healing: histomorphometric evaluation. Turk J Med Sci 201623;46(4):1203-1208.
  42. Ornstrup MJ, Harslof T, Kjaer TN, Langdahl BL, Pedersen SB. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial. J Clin Endocrinol Metab 2014;99(12):4720–4729
  43. Cottart C, Nivet-Antoine V, Laguillier-Morizot, Beaudeux J. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 2010;54(1):7–16
  44. Williams LD, Burdock GA, Edwards JA, Beck M, Bausch J. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol 2009;47(9):2170–2182
  45. Cottart, CH, V Nivet-Antoine, Beaudeux JL. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res 2014;58(1):7–21.
  46. Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS. Resveratrol modulates drug- and carcinogen metabolizing enzymes in a healthy volunteer study. Cancer Prev Res 2010;3(9):1168–1175.
  47. Brown VA, Patel KR, Viskaduraki M, Crowell JA. Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, Brenner DE. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010; 70(22):9003-9011.
  48. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, Brenner DE, Steward WP, Gescher AJ, Brown K. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010;70(19):7392–7399.
  49. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stødkilde-Jørgensen H, Møller N, Jessen N, Pedersen SB, Jørgensen JO. High-Dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013;62(4):1186-1195.
  50. Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, Brown K, Steward WP, Gescher AJ. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases– safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila) 2011;4(9):1419–1425.
  51. la Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, Singhal N, Cameron DW. Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 2010; 49(7):449-454.
  52. Crandall JP, Oram V, Trandafirescu G, Reid M, Kishore P, Hawkins M, Cohen HW, Barzilai N. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci 2012;67(12):1307-1312.
  53. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, Brenner DE. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007;16(6):1246-1252.
  54. Tou JC. Resveratrol supplementation affects bone acquisition and osteoporosis: Pre-clinical evidence toward translational diet therapy. Biochim Biophys Acta. 2015;1852(6):1186-1194.